

Conflict of Interest Disclosures

00000428601 Andrew W. Roberts, MBBS, PhD

Last Confirmed Date:08/08/2025

Company	Relationship	Additional Information	End Date
Cancer Council of Victoria	Membership on a Board or Advisory Committee	Member of Medical and Scientific Advisory Committee Not for profit organisation - State	Is Current
South Australian immunoGENomics Cancer Institute (SAiGENCI)	Membership on a Board or Advisory Committee	Member, Scientific Advisory Board	Is Current
Genentech	Patents & Royalties	Employee of Walter and Eliza Hall Institute which receives milestone payments relating to ABT-199	Is Current
Abbott			Is Current
Genentech			Is Current
Victorian Comprehensive Cancer Centre	Membership on a Board or Advisory Committee	Member of board of management of Victorian Comprehensive Cancer Centre from Sept 2021	Is Current
Johnson and Johnson	Research Funding	Lab receives funding for contract research	Is Current
AbbVie	Patents & Royalties	My employer, the Walter and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of venetoclax. Under the Institute's commercialization policy, I am eligible to receive a small fraction of these royalties (from Oct 2018). I also hold a patent related to venetoclax, wholly assigned to AbbVie and for which I receive no financial benefit.	Is Current
Abbvie (formerly Abbott)	Patents & Royalties	My employer, the Walter and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of ABT-199. Under the Institute's commercialization policy, I am eligible to receive and do receive a fraction of these royalties (from Oct 2018). I also hold a patent related to venetoclax, wholly assigned to AbbVie and for which I receive no financial benefit.	Is Current
AbbVie	Research Funding	Funding for an investigator initiated clinical trial. Paid to institution.	Is Current
Walter and Eliza	Patents &	My employer, the Walter and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of venetoclax (formerly ABT-199). Under	Is

Hall Institute of Medical Research	Royalties	the Institute's commercialization policy, I am eligible to receive and do receive a fraction of these royalties (from Oct 2018).	Current
Genentech	Patents & Royalties	My employer, the Walter and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of venetoclax. Under the Institute's commercialization policy, I am eligible to receive and do receive a fraction of these royalties (from Oct 2018). I also hold a patent related to venetoclax, wholly assigned to AbbVie and for which I receive no financial benefit.	Is Current

